MaxCyte公司2025年季度报告

Table of Contents NoPARTI. FINANCIAL INFORMATIONItem1.Condensed Consolidated Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Changes in Stockholders’ EquityCondensed Consolidated Statements of Cash FlowsNotesto Unaudited Condensed Consolidated Financial StatementsItem2.Management’s Discussion and Analysis of Financial Condition and Resultsof OperationsItem3.Quantitative and Qualitative Disclosures About Market RiskItem4.Controls and ProceduresPARTII. OTHER INFORMATIONItem1.Legal ProceedingsItem1A.Risk FactorsItem2.Unregistered Sales of Equity Securities and Use of ProceedsItem3.Defaults Upon Senior SecuritiesItem4.Mine Safety DisclosuresItem5.Other InformationItem6.ExhibitsSignatures PART I. FINANCIAL INFORMATION MaxCyte,Inc.Unaudited Condensed Consolidated Statements of Operations MaxCyte, Inc.Notes to Unaudited Condensed Consolidated Financial Statements(in thousands, except par value, share and per share amounts) 1.Organization and Description of Business MaxCyte, Inc. (the “Company” or “MaxCyte”) was incorporated as a majority-owned subsidiary ofEntreMed, Inc. (“EntreMed”) on July 31, 1998, under the laws and provisions of the State ofDelawareand commenced operations on July 1,1999.In November 2002,MaxCyte was MaxCyte is a global life sciences company focused on advancing the discovery, development, andcommercializationof next-generation cell therapies.MaxCyte leverages its proprietary cellengineering technology platform to enable the programs of its biotechnology and pharmaceuticalcompany customers who are engaged in cell therapy, including gene gene-editing and immuno-oncology, as well as in drug discovery and development and biomanufacturing. The Company The Company’s registration statement on Form S-1 related to its initial public offering of commonstock (the “IPO”) in the United States of America (the “U.S.”) was declared effective on July 29,2021, and the Company’s common stock began trading on the Nasdaq Global Select Market on July30, 2021. On August 3, 2021, the Company sold15,525,000shares of common stock in the IPO at aprice to the public of $13.00per share, inclusive of2,025,000shares issued pursuant to the full 2.Summary of Significant Accounting Policies Basis of Presentation Theaccompanying unaudited condensed consolidated interim financial statements have beenprepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) forinterim financial information and pursuant to the instructions to Form10-Q and Article 8 ofRegulation S-X of the U.S. Securities and Exchange Commission (the “SEC”). In the Company’sopinion,the accompanying unaudited condensed consolidated financial statements include alladjustments, consisting of both normal recurring adjustments, and adjustments for material unusual orinfrequently occurring transactions or events, which are necessary to present fairly the Company’sfinancial position, results of operations, and cash flows as of and for the periods presented. TheCompany recorded material accounting entries in the interim period ended March 31, 2025 for thepreliminary purchase accounting for SeQure, Dx Inc. (“SeQure”) described in Note 8. The condensed Table of Contents Significant Accounting Policies The Company’s significant accounting policies are disclosed in the notes to its audited consolidatedfinancial statements for theyear ended December31, 2024 included in the 2024 Form 10-K and have Basis of Consolidation The condensed consolidated financial statements include the accounts of the Company and itswholly-owned subsidiaries, SeQure and CCTI, Inc. All significant intercompany balances have been Concentration of Risk TheCompany maintains its cash and cash equivalents with three financial institutions thatmanagement believes to be of high credit quality. At times, the Company’s cash balances may exceedfederally insured limits and cash may also be deposited in foreign bank accounts that are not covered Significant customers are those that accounted for 10% or more of the Company’s total revenue forthe period or accounts receivable as of the end of a reporting period. During the three monthsendedMarch 31, 2025,onecustomer represented29% of revenue, and another customer represented14% ofrevenue.During the three months ended March 31, 2024,onecustomer represented23% of revenueand another customer represented18% of revenue. As of March 31, 2025,onecustomer accounted Certain components included in the Company’s products are obtained from a single source or alimited group of suppliers. During the three months ended March 31, 2025,22% of the Company’sadditions to inventory were fromonesupplier. During the three months ended March 31, 2024,30%of the Company’s additions to inventory were fromonesupplier.As of March 31, 2025 and Accounts Receivable Accounts receivable are reduced by an allowance for credit losses, if ne